Post-marketing study design to evaluate the effectiveness of the 9-valent and 4-valent HPV vaccines on serious HPV-related cervical disease in China
The 4-valent (4 v) and 9-valent (9 v) human papillomavirus (HPV) vaccines are approved in China for females aged 9–45 years. However, the real-world impact of 4vHPV or 9vHPV vaccination for the prevention of high-grade cervical disease in Chinese women is lacking. Two post-marketing surveillance stu...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , , , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
Taylor & Francis Group
2024-12-01
|
| Sraith: | Human Vaccines & Immunotherapeutics |
| Ábhair: | |
| Rochtain ar líne: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2418168 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|